DHR — Danaher Corp
NYSE · Life Sciences Tools & Services · Life Sciences Tools & Services
- Latest Close
- $178.57
- 30-Day Move
- -19.8%
- Market Cap
- $135.1B
- Shares Outstanding
- 707,140,000
- P/E Ratio
- 37.4
- P/B Ratio
- 3.08
Analyst consensus: Buy · 30 analysts
Danaher Corp
A read-only Alphactor snapshot forDanaher Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$178.57
30-Day Move
-19.8%
Market Cap
$135.1B
Shares Outstanding
707,140,000
P/E Ratio
37.4
P/B Ratio
3.08
$178.57
-19.8%last 90 delayed daily bars
90D High
$242.80
90D Low
$175.00
Avg Volume
4,011,091
Gross margin is running at 59.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 14.7%, useful for comparing DHR against peers in Life Sciences Tools & Services.
DHR is down 19.8% over the last 30 trading days shown on this page.
Latest operating income is $1.5B, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$99.11
Rule of 40
24.3%
Latest Close
$178.57
30-Day Move
-19.8%
Market Cap
$135.1B
Shares Outstanding
707,140,000
P/E Ratio
37.4
P/B Ratio
3.08
ROE
6.9%
ROA
4.3%
Gross Margin
59.2%
Operating Margin
19.1%
Net Margin
14.7%
Debt / Equity
0.35
Current Ratio
1.87
Dividend Yield
88.1%
Latest Revenue
$6.8B
Revenue
$6.8B
Gross Profit
$4.0B
Operating Income
$1.5B
Net Income
$1.2B
Gross Margin
5923.0%
Net Margin
1471.0%
Current Ratio
1.87
Debt / Equity
0.35
Fair Value
$99.11
Upside / Downside
-44.5%
Signal
Overvalued
Implied Growth
8.0%
DCF
$86.49
EPV
$58.45
EV/Rev
$152.39
Growth Assumption
-2.7%
Discount Rate
7.7%
Terminal Growth
2.0%
Base FCF
$5.3B
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Altman Z
3.97
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
1.78x
Rule of 40
24.3%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $26.6B | $7.5B | $7.2B | $7.4B |
| 2023-12-31 | $23.9B | $5.2B | $4.8B | $5.8B |
| 2024-12-31 | $23.9B | $4.9B | $3.9B | $5.3B |
| 2025-12-31 | $24.6B | $4.7B | $3.6B | $5.3B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$115M
Buys
0
Sells
13
Buy Value
$0
Sell Value
$115M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-01 | Gugino Matthew E | A | 10,778 | $0.00 |
| 2026-03-01 | Gugino Matthew E | F | 231 | $210.64 |
| 2026-03-01 | Gugino Matthew E | A | 3,988 | $0.00 |
| 2026-03-01 | Milosevich Gregory M | A | 11,548 | $0.00 |
| 2026-03-01 | Milosevich Gregory M | F | 118 | $210.64 |
| 2026-03-01 | Milosevich Gregory M | A | 4,273 | $0.00 |
| 2026-03-01 | Sawyer Montgomery Julie A | A | 16,681 | $0.00 |
| 2026-03-01 | Sawyer Montgomery Julie A | F | 1,080 | $210.64 |
Two Sigma Advisers
Filed 2026-02-17
--
--
Vanguard Group
Filed 2026-01-29
$14.0B
+0.1%
BlackRock
Filed 2024-08-13
$12.6B
--
FMR LLC (Fidelity)
Filed 2026-02-17
$4.5B
+28.8%
Geode Capital Management
Filed 2026-02-09
$3.1B
-0.5%
Northern Trust
Filed 2026-02-17
$1.7B
-2.1%
4.23
Consensus
Buy—
—
—
30
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.